Meropenem Actavis (Meropenem)

Meropenem belongs to the carbapenem class of β‑lactam antibiotics. It binds to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic lysis and bacterial death. Its stability against most β‑lactamases expands its spectrum of activity.

The dose of Meropenem Actavis is individualized by the prescribing clinician based on the type and severity of infection, the patient’s renal function, weight and age. Typical regimens range from 500 mg to 2 g administered intravenously every 8 hours, but exact dosing must be determined by a qualified healthcare professional.

Safety data for Meropenem in pregnancy and lactation are limited. The drug should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Breastfeeding mothers should consult their physician, as the medication may be excreted in breast milk.

To place an order, submit an enquiry on the Meropenem Actavis product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Meropenem offers a broad spectrum of activity against many Gram‑negative, Gram‑positive and anaerobic bacteria, and it is stable against most β‑lactamases. Compared with imipenem‑cilastatin, meropenem has a lower risk of seizures and does not require co‑administration of a renal dehydropeptidase inhibitor. It is often chosen when resistance to other β‑lactams is suspected.

Meropenem Actavis for injection must be stored refrigerated at 2 °C to 8 °C. The vial should be kept in its original packaging, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product label and kept refrigerated if not administered immediately.

Meropenem Actavis is supplied as a sterile powder for injection. It is reconstituted with the appropriate diluent and administered intravenously, usually over 15–30 minutes. The infusion rate and duration are determined by the prescriber, taking into account the infection type and patient-specific factors such as renal function.

Serious adverse events include seizures (particularly in patients with renal impairment or pre‑existing CNS disorders), severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, and significant renal or hepatic dysfunction. Prompt medical attention is required if any of these events occur.

Meropenem Actavis should not be used in individuals with a documented hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with a history of seizures, severe renal impairment, or known colonization with carbapenem‑resistant organisms, unless no alternative therapy is available.